BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 11695559)

  • 1. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens.
    French J; Storer RD; Donehower LA
    Toxicol Pathol; 2001; 29 Suppl():24-9. PubMed ID: 11695559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and characterization of potential human carcinogens using B6.129tm1Trp53 heterozygous null mice and loss of heterozygosity at the Trp53 locus.
    French JE
    IARC Sci Publ; 2004; (157):271-87. PubMed ID: 15055301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent.
    French JE; Lacks GD; Trempus C; Dunnick JK; Foley J; Mahler J; Tice RR; Tennant RW
    Carcinogenesis; 2001 Jan; 22(1):99-106. PubMed ID: 11159747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing.
    Venkatachalam S; Tyner SD; Pickering CR; Boley S; Recio L; French JE; Donehower LA
    Toxicol Pathol; 2001; 29 Suppl():147-54. PubMed ID: 11695551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome 11 allelotypes reflect a mechanism of chemical carcinogenesis in heterozygous p53-deficient mice.
    Hulla JE; French JE; Dunnick JK
    Carcinogenesis; 2001 Jan; 22(1):89-98. PubMed ID: 11159746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53+/- hemizygous knockout mouse: overview of available data.
    Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
    Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: nature of the models.
    van Steeg H; de Vries A; van Oostrom CTh ; van Benthem J; Beems RB; van Kreijl CF
    Toxicol Pathol; 2001; 29 Suppl():109-16. PubMed ID: 11695546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xpa and Xpa/p53+/- knockout mice: overview of available data.
    van Kreijl CF; McAnulty PA; Beems RB; Vynckier A; van Steeg H; Fransson-Steen R; Alden CL; Forster R; van der Laan JW; Vandenberghe J
    Toxicol Pathol; 2001; 29 Suppl():117-27. PubMed ID: 11695547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
    Cohen SM
    Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal mouse model: review of methods and results.
    McClain RM; Keller D; Casciano D; Fu P; MacDonald J; Popp J; Sagartz J
    Toxicol Pathol; 2001; 29 Suppl():128-37. PubMed ID: 11695548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Tg rasH2 mouse in cancer hazard identification.
    Morton D; Alden CL; Roth AJ; Usui T
    Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of genotoxic and non-genotoxic carcinogens in Xpc(-/-)p53(+/-) mice.
    Melis JP; Speksnijder EN; Kuiper RV; Salvatori DC; Schaap MM; Maas S; Robinson J; Verhoef A; van Benthem J; Luijten M; van Steeg H
    Toxicol Appl Pharmacol; 2013 Jan; 266(2):289-97. PubMed ID: 23153559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,3-butadiene: cancer, mutations, and adducts. Part III: In vivo mutation of the endogenous hprt genes of mice and rats by 1,3-butadiene and its metabolites.
    Walker VE; Meng Q
    Res Rep Health Eff Inst; 2000 Mar; (92):89-139; discussion 141-9. PubMed ID: 10925840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens.
    Eastin WC; Haseman JK; Mahler JF; Bucher JR
    Toxicol Pathol; 1998; 26(4):461-73. PubMed ID: 9715504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CB6F1-rasH2 mouse: overview of available data.
    Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
    Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of target organs of carcinogenicity for mutagenic and non-mutagenic chemicals.
    Gold LS; Slone TH; Stern BR; Bernstein L
    Mutat Res; 1993 Mar; 286(1):75-100. PubMed ID: 7678909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity and carcinogenicity studies of chlorpromazine hydrochloride and p-cresidine in the p53 heterozygous mouse model.
    Petruska JM; Frank DW; Freeman GB; Evans EW; MacDonald JS
    Toxicol Pathol; 2002; 30(6):696-704. PubMed ID: 12512871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically altered mouse models for identifying carcinogens.
    Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
    IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
    [No Abstract]   [Full Text] [Related]  

  • 19. Lack of susceptibility of heterozygous p53-knockout CBA and CIEA mice to phenolphthalein in a 6-month carcinogenicity study.
    Okamura M; Kashida Y; Watanabe T; Yasuhara K; Onodera H; Hirose M; Usui T; Tamaoki N; Mitsumori K
    Toxicology; 2003 Mar; 185(1-2):17-22. PubMed ID: 12505441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of hormonal carcinogenesis in the p53+/- hemizygous knockout mouse: studies with diethylstilbestrol.
    Carmichael PL; Mills JJ; Campbell M; Basu M; Caldwell J
    Toxicol Pathol; 2001; 29 Suppl():155-60. PubMed ID: 11695552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.